Clinical trial · Interventional
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
NCT03381352CI-TRIAL-00031429unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine | Drug | Capecitabine | ALIAS |
| Chemo-radiotherapy with IMRT technique | Radiation | — | UNRESOLVED |
| Mitomycin C | Drug | Mitomycin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemo-radiotherapy with IMRT technique
- description
- Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
- interventionNames
- Radiation: Chemo-radiotherapy with IMRT technique
- Drug: Capecitabine
- Drug: Mitomycin C
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 8 weeks after IMRT
- description
- To evaluate response rate of IMRT with chemotherapy
Secondary outcomes (1)
- measure
- Adverse events
- timeFrame
- from start of IMRT to 8 weeks after IMRT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * CT/MRI diagnosed stage cT1-4N0-3; * Histologically confirmed anal squamous carcinoma; * KPS \>= 70 * Adequate organ function; * No previous radiotherapy or chemotherapy; * No surgery. Exclusion Criteria: * Previous malignant cancer history; * Allegic to 5-fu or MMC
References
Publications (0)
Data not yet available
No reference posted for this study.